Methylisopropyllysergamide (MIPLA), also known as lysergic acid methylisopropyl amide, is an analog of LSD discovered initially by Albert Hofmann at Sandoz during the initial research on LSD’s structure-activity relationship. Further investigations into MIPLA have been conducted by a team led by David E. Nichols at Purdue University. MIPLA is a structural isomer of LSD, where the alkyl groups on the amide nitrogen have undergone a methylene shuffle. In terms of potency, MIPLA, along with its ethylisopropyl counterpart, are the only simple N, N-dialkyl lysergamides that come close to matching the power of LSD itself, being approximately 1/3 to 1/2 as potent as LSD. In contrast, other dialkyl analogs, like dimethyl, dipropyl, methyl ethyl, etc., are only around 1/10 as potent as LSD. Some N-monoalkyl lysergamides, such as sec-butyl and t-butyl derivatives, have shown a potency and activity profile comparable to LSD. The mono-isopropyl derivative is slightly weaker than MIPLA.
Despite its lower potency, the hallucinogenic effects of MIPLA are similar to those of LSD. MIPLA has primarily been used in research to study the binding site at the 5-HT2A receptor, which is the primary site through which LSD exerts most of its pharmacological effects.

IUPAC name
CAS Number100768-08-9 
PubChem CID57507938
Chemical and physical data
Molar mass323.440 g·mol−1


1. What is Methylisopropyllysergamide (MIPLA)?

  • MIPLA, also known as lysergic acid methylisopropyl amide, is a chemical compound and an analog of LSD (lysergic acid diethylamide). It was initially discovered during early LSD research.

2. How does MIPLA compare to LSD in terms of potency?

  • MIPLA is one of the few lysergamides that comes close to the potency of LSD. It is approximately 1/3 to 1/2 as potent as LSD, making it one of the more potent lysergamides.

3. What are the effects of MIPLA?

  • MIPLA produces hallucinogenic effects that are similar to those of LSD. Users may experience altered perceptions, changes in sensory experiences, and shifts in consciousness. The specific products can vary from person to person.

4. Are there any known medical uses for MIPLA?

  • MIPLA is primarily used for research purposes, particularly in studies on the 5-HT2A receptor, the main target through which LSD exerts its effects. It is not approved for medical use.

5. Is MIPLA legal?

  • The legal status of MIPLA varies by country. In some places, it may be considered a controlled substance or an analog of LSD, while in others, it may not be precisely regulated.

6. Is MIPLA safe to use?

  • Like other hallucinogenic substances, MIPLA should be used with caution. Its safety profile, long-term effects, and potential risks have not been extensively studied. Users should know the possible psychological and physiological effects and take appropriate precautions.

7. Can MIPLA cause hallucinogenic experiences similar to LSD?

  • Yes, MIPLA is known to produce hallucinogenic effects that are akin to those of LSD. Users may experience visual distortions, altered thought patterns, and changes in perception while under its influence.

8. Is MIPLA available for recreational use?

  • MIPLA is primarily used in research settings and is not commonly found in recreational drug markets. Its availability may be limited compared to more well-known substances.

9. Can MIPLA be detected in standard drug tests?

  • Standard drug tests typically do not screen for MIPLA precisely. However, it may be detected as an LSD analog in tests that check for lysergic acid derivatives.

10. Is MIPLA addictive?

– There is no evidence to suggest that MIPLA is physically addictive. However, like other hallucinogens, it is not typically associated with addiction in the same way that some other substances are.


1. Règlement du 20 mai 2021 modifiant l’arrêté du 22 février 1990 établissant la liste des substances classées comme stupéfiants. Cette modification réglementaire, enregistrée sur le 20 mai 2021, a des implications importantes dans la classification des substances psychoactives en France.

2. Études sur les dérivés de N-isopropyl lysergamide. En mars 1994, des chercheurs ont mené des études de discrimination de médicaments et des études de liaison aux récepteurs des dérivés de N-isopropyl lysergamide. Leurs découvertes ont des implications significatives dans la compréhension des interactions de ces composés avec les récepteurs du cerveau.

3. La découverte de la LSD et de ses aspects chimiques et pharmacologiques. En juin 1959, le Dr. Albert Hofmann, célèbre pour la synthèse de la LSD, a publié des recherches sur les aspects chimiques et pharmacologiques des médicaments psychotomimétiques. Ses travaux ont jeté les bases de la compréhension de ces composés.

4. Brevet américain sur les amides de l’acide lysergique. En 1961, un brevet américain (US patent 2997470) a été accordé à Pioch RP pour les amides de l’acide lysergique. Ce brevet a eu un impact sur le développement ultérieur de ces composés.

5. Les cousins de la LSD et leur rôle dans la recherche psychédélique. En 2001, le Dr. David E. Nichols a examiné la LSD et ses cousins lysergamides dans le contexte de la recherche psychédélique. Ses travaux ont contribué à élargir notre compréhension de ces substances.

Leave a Comment

Your email address will not be published. Required fields are marked *